专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2020005934A1 POZIOTINIB COMBINATIONS WITH AN ANTI-HER1, HER2 OR HER4 ANTIBODY AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2020005934A1
公开(公告)日：2020-01-02
申请号：PCT/US2019/038974
申请日：2019-06-25
申请人： SPECTRUM PHARMACEUTICALS, INC. , HANMI PHARMACEUTICAL CO., LTD.
发明人： REDDY, Guru , JANG, Sunyoung , BYUN, Jooyun
IPC分类号： A61K31/395 , A61K31/436 , A61K31/444 , A61K31/517
摘要： Provided are combinations of poziotinib and an anti-HER1, anti-HER2 or anti-HER4 antibody, optionally with other agents, and use of the combinations for treating cancer.

22. 发明申请

WO2018059502A1 HETERODIMERIC IMMUNOGLOBULIN CONSTRUCTS AND PREPARATION METHODS THEREOF 审中-公开
标题翻译：异二聚体免疫球蛋白构建体及其制备方法
公开(公告)号：WO2018059502A1
公开(公告)日：2018-04-05
申请号：PCT/CN2017/104044
申请日：2017-09-28
申请人： BEIJING HANMI PHARMACEUTICAL CO., LTD.
发明人： LIU, Jiawang , SONG, Nanmeng , YANG, Dongge , YANG, Yaping , KIM, Maengsup
IPC分类号： C07K16/00 , A61K39/395 , C12N15/13 , A61P37/02 , A61P35/00
摘要： Provided is a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.
摘要翻译：提供了产生稳定的和高度特异性的异二聚体免疫球蛋白构建体（例如双特异性抗体）的方法，其保留天然IgG的期望特性并且缺乏不需要的重链 - 轻链错配，其可以同时结合两个靶分子，在治疗复杂疾病方面更有效。

23. 发明申请

WO2013056679A1 NOVEL HETEROARYL-AMINO DERIVATIVES 审中-公开
标题翻译：新型异喹啉衍生物
公开(公告)号：WO2013056679A1
公开(公告)日：2013-04-25
申请号：PCT/CN2012/083248
申请日：2012-10-19
申请人： BEIJING HANMI PHARMACEUTICAL CO., LTD
发明人： ZHANG, Bo , YANG, Jun , LIU, Jinming , HUANG, Hai , WU, Yong , TAO, Ran , XU, Jiangcheng , SHEN, Ning , MOON, Sunghwan , KIM, Maengsup
IPC分类号： C07D403/12 , C07D413/12 , C07D417/12 , A61K31/502 , A61P3/06 , A61P3/10
CPC分类号： C07D403/12 , A61K45/06 , C07D239/42 , C07D239/78 , C07D413/12 , C07D417/12 , C07D417/14 , C07D513/04
摘要： Disclosed is a compound of formula (I), wherein R 1 , R 2 , L, R m and R n are as defined herein. The compound of formula (I) may be used in preventing and/or treating acyl CoA-diacylglycerol acyltransferase 1(DGAT-1) related diseases, such as obesity, coronary disease, hypertension, hyperlipidemia, arteriosclerosis, type II diabetes, stroke, hepatitis C, and the like.
摘要翻译：公开了式（I）的化合物，其中R 1，R 2，L，R m和R n如本文所定义。式（I）化合物可用于预防和/或治疗相关的酰基辅酶A - 二酰基甘油酰基转移酶1（DGAT-1）相关疾病，如肥胖症，冠心病，高血压，高脂血症，动脉硬化，II型糖尿病，中风，肝炎 C等。

24. 发明申请

WO2013036032A1 A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING INTERFERON ALPHA CONJUGATE 审中-公开
标题翻译：用于治疗癌症的药物组合物，包括干扰素ALPHA联合
公开(公告)号：WO2013036032A1
公开(公告)日：2013-03-14
申请号：PCT/KR2012/007113
申请日：2012-09-05
申请人： HANMI SCIENCE CO., LTD. , BEIJING HANMI PHARMACEUTICAL CO., LTD. , JUNG, Sung Youb , WOO, Young Eun , LIM, Se Young , CHOI, In Young , LEE, Jae Ho , KWON, Se Chang , MOON, Sung Hwan , LIU, Jiawang
发明人： JUNG, Sung Youb , WOO, Young Eun , LIM, Se Young , CHOI, In Young , LEE, Jae Ho , KWON, Se Chang , MOON, Sung Hwan , LIU, Jiawang
IPC分类号： A61K38/21 , A61K39/395 , A61K47/48 , A61K47/30 , A61P35/00
CPC分类号： A61K47/642 , A61K9/0019 , A61K31/7068 , A61K38/212 , A61K47/60 , A61K47/68
摘要： The present invention relates to an anti-cancer pharmaceutical composition comprising an interferon alpha or a polymer congugate thereof and use thereof in the treatment of cancer by co-administration with anti-cancer agents. The interferon alpha conjugate of the present invention shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition of the present invention has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.
摘要翻译：本发明涉及包含干扰素α或其聚合物结合物的抗癌药物组合物及其在通过与抗癌药物共同给药治疗癌症中的用途。本发明的干扰素α结合物比常规的干扰素α显示出更长的体内半衰期和更优异的抗癌活性，特别是与抗癌药如吉西他滨的共同给药具有协同抑制作用对癌细胞生长和增殖的影响，以显示非常优异的抗癌活性。此外，本发明的抗癌药物组合物具有优异的体内半衰期和抗癌活性，从而大大降低给药频率。共同施用抗癌剂和具有优异抗癌活性的干扰素α缀合物降低了抗癌剂的施用剂量，从而降低了抗癌剂的副作用并增加了患者的治疗依从性。

25. 发明申请

WO2009069983A3 A PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE 审中-公开
公开(公告)号：WO2009069983A3
公开(公告)日：2009-06-04
申请号：PCT/KR2008/007074
申请日：2008-11-28
申请人： HANMI PHARMACEUTICAL CO., LTD. , SONG, Dae Hae , KIM, Min Young , PARK, Young Jin , KANG, Eun Hee , JUNG, Sung Youb , KWON, Se Chang , LEE, Gwan Sun
发明人： SONG, Dae Hae , KIM, Min Young , PARK, Young Jin , KANG, Eun Hee , JUNG, Sung Youb , KWON, Se Chang , LEE, Gwan Sun
IPC分类号： A61K38/16 , A61P3/04 , A61K39/395
摘要： The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases.

26. 发明申请

WO1997034864A1 STEREOSELECTIVE PROCESS FOR PREPARATION OF (2R,3S)-'beta'-PHENYLISOSERINE DERIVATIVE 审中-公开
标题翻译：制备（2R，3S） - β-苯并二氢吡喃衍生物的立体选择性方法
公开(公告)号：WO1997034864A1
公开(公告)日：1997-09-25
申请号：PCT/KR1997000041
申请日：1997-03-19
申请人： HANMI PHARMACEUTICAL CO., LTD. , KIM, Wan, Joo , LEE, Gwan, Sun , CHAI, Ki, Byung , KIM, Kyoung, Soo , MOON, Young, Ho , KIM, Nam, Du , LEE, Kwang, Ok , HA, Tae, Hee
发明人： HANMI PHARMACEUTICAL CO., LTD.
IPC分类号： C07C229/34
CPC分类号： C07C227/32
摘要： The present invention relates to a novel stereoselective process for preparing the (2R,3S)- beta -phenylisoserine derivative represented by formula (1), which can be used as an intermediate for synthesizing the terpene taxan derivatives paclitaxel and taxotere. In said formula, R1 represents hydrogen, benzoyl or t-butoxycarbonyl, and R2 represents hydrogen, C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkynyl or benzyl.
摘要翻译：本发明涉及一种制备式（1）所示的（2R，3S）-β-苯基异丝氨酸衍生物的新型立体选择性方法，其可用作合成萜烯紫杉醇衍生物紫杉醇和泰索帝的中间体。在所述式中，R 1表示氢，苯甲酰基或叔丁氧基羰基，R 2表示氢，C 1 -C 4烷基，C 1 -C 4烯基，C 1 -C 4炔基或苄基。

27. 发明申请

WO1992012155A1 NOVEL QUINOLONE COMPOUNDS AND PROCESSES FOR PREPARATION THEREOF 审中-公开
标题翻译：新型喹啉酮化合物及其制备方法
公开(公告)号：WO1992012155A1
公开(公告)日：1992-07-23
申请号：PCT/KR1992000003
申请日：1992-01-14
申请人： HANMI PHARMACEUTICAL CO., LTD. , MOON, Soon, Ku , LEE, Gwan, Sun , RYOO, Eui, Sang , CHANG, Young, Kil , MOON, Young, Ho , KIM, Sang, Tae , CHUN, Jong, Pil , KOH, Joon, Hyung , GIL, Young, Hwan
发明人： HANMI PHARMACEUTICAL CO., LTD.
IPC分类号： C07D487/08
CPC分类号： C07D487/04 , Y02P20/55
摘要： This invention relates to the novel quinolone compound of formula (I) having excellent antimicrobial activity both against gram positive and negative bacteria, its pharmaceutically acceptable salt, and the process for preparation thereof; wherein R is hydrogen or protective group, R is hydrogen, amino, alkylamino from one to four carbon atoms, hydroxy, alkoxy from one to four carbon atoms, mercapto, alkylthio from one to four carbon atoms, or halogen, R is alkyl from one to four carbon atoms, alkenyl from two to four carbon atoms, cycloalkyl from three to six carbon atoms, haloalkyl, hydroxyalkyl from two to four carbon atoms, methoxy, amino, alkylamino from one to two carbon atoms, dimethylamino, or optionally substituted phenyl with more than one of halogen atoms or alkyl from one to three carbon atoms, Z is an amine of formula (II), (wherein R is hydrogen or alkyl from one to four carbon atoms, R and R are, same or different, hydrogen or alkyl from one to two carbon atoms), X is N or C-R (wherein R is hydrogen, hydroxy, methyl, cyano, nitro, methoxy, halogen, or can form a bridge of formula (a), (b), (c) or (d) with R .
摘要翻译：本发明涉及对革兰氏阳性细菌和阴性细菌具有优异的抗微生物活性及其药学上可接受的盐的式（I）的新型喹诺酮化合物及其制备方法; 其中R 1为氢或保护基，R 2为氢，氨基，1至4个碳原子的烷基氨基，羟基，1至4个碳原子的烷氧基，1至4个碳原子的巯基，烷硫基，或卤素 R 3为1至4个碳原子的烷基，2至4个碳原子的烯基，3至6个碳原子的环烷基，2至4个碳原子的卤代烷基，羟基烷基，甲氧基，氨基，1至2个碳原子的烷基氨基原子，二甲基氨基或具有多于一个卤素原子或1-3个碳原子的任选取代的苯基，Z是式（II）的胺，其中R 4是氢或1-4个碳原子的烷基 R 5和R 7相同或不同，氢或一至两个碳原子的烷基），X是N或CR 6（其中R 6是氢，羟基，甲基，氰基，硝基，甲氧基，卤素，或可以与R 3形成式（a），（b），（c）或（d）的桥。

28. 发明授权

US11753471B2 Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing same 有权
公开(公告)号：US11753471B2
公开(公告)日：2023-09-12
申请号：US16968241
申请日：2019-02-08
申请人： BEIJING HANMI PHARMACEUTICAL CO., LTD. , INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
发明人： Jiawang Liu , Nanmeng Song , Yaping Yang , Maeng Sup Kim , Yao Yan , Qingqing Yin
IPC分类号： C07K16/00 , C07K16/28 , A61P35/00 , C07K16/32 , A61K39/00
CPC分类号： C07K16/2818 , A61P35/00 , C07K16/32 , A61K2039/505 , C07K2317/31 , C07K2317/52 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2317/90
摘要： Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. More particularly, provided are a highly stable heterodimeric anti-PD-1/anti-HER2 bispecific antibody having natural IgG characteristics without mismatch between a heavy chain and a light chain, and a method of preparing the same. The bispecific antibody may bind to two target molecules simultaneously and has excellent effects in treatment of a complex disease.

29. 发明申请

US20220281972A1 FORMULATION COMPRISING ANTI-PD-1/HER2 BISPECIFIC ANTIBODY, METHOD FOR PREPARING SAME AND USE THEREOF 有权
公开(公告)号：US20220281972A1
公开(公告)日：2022-09-08
申请号：US17631641
申请日：2020-08-06
申请人： INNOVENT BIOLOGICS (SUZHOU) CO., LTD. , BEIJING HANMI PHARMACEUTICAL CO., LTD.
发明人： Yanghan LIU , Yidong MA , Yinjue WANG , Kaisong ZHOU
IPC分类号： C07K16/28 , A61K47/26 , A61K9/00 , A61P35/00
摘要： The present invention relates to formulations comprising an anti-PD-1/HER2 bispecific antibody, and in particular to a pharmaceutical formulation comprising the anti-PD-1/HER2 bispecific antibody, a buffer, a stabilizer and a surfactant. Furthermore, the present invention also relates to therapeutic or prophylactic use of these formulations.

30. 发明授权

US10696675B2 Imidazopyridopyrimidine derivative compound and use thereof 有权
公开(公告)号：US10696675B2
公开(公告)日：2020-06-30
申请号：US16313778
申请日：2017-06-28
申请人： HANMI PHARMACEUTICAL CO., LTD.
发明人： Moon Sub Lee , Eun Young Byun , Ji Sook Kim , Won Jeoung Kim , Nam Du Kim , Seung Hyun Jung , Young Gil Ahn
IPC分类号： C07D471/14 , A61K31/519 , C07D487/14 , A61P35/00
摘要： A novel imidazopyridine derivative compound and uses thereof are disclosed. An imidazopyridopyridine derivative compound of Chemical Formula 1 having selective inhibitory activity for a fibroblast growth factor receptor (FGFR) and a pharmaceutical composition including the compound are disclosed:

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式